Sera from anti-Jo-1-positive patients with polymyositis and interstitial lung disease induce expression of intercellular adhesion molecule 1 in human lung endothelial cells

Arthritis and Rheumatism

Volumn 60, Issue 8, 2009, Pages 2524-2530

  Helmers, Sevim Barbasso ^a   Englund, Pernilla ^a   Engström, Marianne ^a   Åhlin, Erik ^b   Fathi, Maryam ^a   Janciauskiene, Sabina ^c   Heimbürger, Mikael ^a   Rönnelid, Johan ^b   Lundberg, Ingrid E ^a  

^a KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c LUND UNIVERSITY   (Sweden)

Author keywords

[No Author keywords available]

Indexed keywords

INTERCELLULAR ADHESION MOLECULE 1; JO 1 ANTIBODY; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY;

ADULT; AGED; ANTIGEN EXPRESSION; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; ENDOTHELIUM CELL; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMAN; HUMAN CELL; IMMUNOFLUORESCENCE; INTERSTITIAL LUNG DISEASE; LUNG ENDOTHELIUM; MALE; POLYMYOSITIS; PRIORITY JOURNAL; SERUM;

ADULT; AGED; ANTIBODIES, ANTINUCLEAR; ENDOTHELIUM, VASCULAR; FEMALE; HISTIDINE-TRNA LIGASE; HUMANS; IMMUNE SERA; IMMUNOGLOBULIN G; INTERCELLULAR ADHESION MOLECULE-1; LUNG; LUNG DISEASES, INTERSTITIAL; MALE; MICROVESSELS; MIDDLE AGED; POLYMYOSITIS; YOUNG ADULT;

EID: 68049108408     PISSN: 00043591     EISSN: 15290131     Source Type: Journal    
DOI: 10.1002/art.24683     Document Type: Article

References (11)

1. Love LA, Leff RL, Fraser DD, Targoff IN, Dalakas M, Plotz PH, et al. A new approach to the classification of idiopathic inflammatory myopathy: myositis-specific autoantibodies define useful homogeneous patient groups. Medicine (Baltimore) 1991;70:360-74.
2. Lundberg I, Kratz AK, Alexanderson H, Patarroyo M. Decreased expression of interleukin-1α, interleukin-1β, and cell adhesion molecules in muscle tissue following corticosteroid treatment in patients with polymyositis and dermatomyositis. Arthritis Rheum 2000;43:336-48.
3. De Bleecker JL, Engel AG. Expression of cell adhesion molecules in inflammatory myopathies and Duchenne dystrophy. J Neuropathol Exp Neurol 1994;53:369-76.
4. Bohan A, Peter JB. Polymyositis and dermatomyositis (first of two parts). N Engl J Med 1975;292:344-7.
5. Eloranta ML, Barbasso Helmers S, Ulfgren AK, Ronnblom L, Alm GV, Lundberg IE. A possible mechanism for endogenous activation of the type I interferon system in myositis patients with anti-Jo-1 or anti-Ro 52/anti-Ro 60 autoantibodies. Arthritis Rheum 2007;56:3112-24.
6. Kumamoto T, Abe T, Ueyama H, Sugihara R, Shigenaga T, Tsuda T. Elevated soluble intercellular adhesion molecule-1 in inflammatory myopathy. Acta Neurol Scand 1997;95:34-7.
7. Kissel JT, Mendell JR, Rammohan KW. Microvascular deposition of complement membrane attack complex in dermatomyositis. N Engl J Med 1986;314:329-34.
8. Mathsson L, Ahlin E, Sjowall C, Skogh T, Ronnelid J. Cytokine induction by circulating immune complexes and signs of in-vivo complement activation in systemic lupus erythematosus are associated with the occurrence of anti-Sjögren's syndrome A antibodies. Clin Exp Immunol 2007;147:513-20.
9. Reefman E, Kuiper H, Limburg PC, Kallenberg CG, Bijl M. Type I interferons are involved in the development of UVB-induced inflammatory skin lesions in systemic lupus erythematosus (SLE) patients. Ann Rheum Dis 2007. E-pub ahead of print.
10. Walsh RJ, Kong SW, Yao Y, Jallal B, Kiener PA, Pinkus JL, et al. Type I interferon-inducible gene expression in blood is present and reflects disease activity in dermatomyositis and polymyositis. Arthritis Rheum 2007;56:3784-92.
11. Lee PY, Li Y, Richards HB, Chan FS, Zhuang H, Narain S, et al. Type I interferon as a novel risk factor for endothelial progenitor cell depletion and endothelial dysfunction in systemic lupus erythematosus. Arthritis Rheum 2007;56:3759-69.